Skip to main
IMRX
IMRX logo

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp demonstrates a strong positive outlook due to significant improvements in overall survival (OS) and progression-free survival (PFS) rates compared to current standard-of-care (SoC) treatments, indicating effective advancements in patient outcomes. The company's drug development programs, utilizing its proprietary computational Disease Cancelling Technology platform, have shown favorable tolerability and safety data, suggesting an edge over both existing therapies and those currently in development. This combination of superior efficacy and safety profiles positions Immuneering favorably in the competitive biopharmaceutical landscape, potentially enhancing its growth and profitability prospects.

Bears say

Immuneering Corp's stock outlook appears negative due to concerns regarding the higher rates of anemia observed in its clinical studies, which may signal underlying issues with the safety profile of its drug candidates. The cited findings, particularly in comparison to the MPACT study, raise questions about the efficacy and tolerability of the company's therapies, potentially affecting investor confidence. Additionally, the implications of these study results may hinder the progress of Immuneering's drug development initiatives and impact future partnerships with pharmaceutical and biotechnology companies.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.